TW200602051A - Pyrazolo[3,4-b]pyridine compound, and its use as a PDE4 inhibitor - Google Patents

Pyrazolo[3,4-b]pyridine compound, and its use as a PDE4 inhibitor

Info

Publication number
TW200602051A
TW200602051A TW094108054A TW94108054A TW200602051A TW 200602051 A TW200602051 A TW 200602051A TW 094108054 A TW094108054 A TW 094108054A TW 94108054 A TW94108054 A TW 94108054A TW 200602051 A TW200602051 A TW 200602051A
Authority
TW
Taiwan
Prior art keywords
compound
pyrazolo
mammal
provides
salt
Prior art date
Application number
TW094108054A
Other languages
English (en)
Chinese (zh)
Inventor
Siegfried Benjamin Christensen Iv
Caroline Mary Cook
Christopher David Edlin
Martin Redpath Johnson
Paul Spencer Jones
Mika Kristian Lindvall
Amyn Pyarali Sayani
Naimisha Trivedi
Lionel Trottet
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0405893A external-priority patent/GB0405893D0/en
Priority claimed from GB0505214A external-priority patent/GB0505214D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of TW200602051A publication Critical patent/TW200602051A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
TW094108054A 2004-03-16 2005-03-16 Pyrazolo[3,4-b]pyridine compound, and its use as a PDE4 inhibitor TW200602051A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0405893A GB0405893D0 (en) 2004-03-16 2004-03-16 Compounds
GB0505214A GB0505214D0 (en) 2005-03-14 2005-03-14 Compounds

Publications (1)

Publication Number Publication Date
TW200602051A true TW200602051A (en) 2006-01-16

Family

ID=34962723

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094108054A TW200602051A (en) 2004-03-16 2005-03-16 Pyrazolo[3,4-b]pyridine compound, and its use as a PDE4 inhibitor

Country Status (15)

Country Link
US (2) US7709497B2 (enExample)
EP (2) EP1735314A1 (enExample)
JP (2) JP2007529464A (enExample)
KR (1) KR20060130744A (enExample)
AR (1) AR048175A1 (enExample)
AU (1) AU2005223351A1 (enExample)
BR (1) BRPI0508843A (enExample)
CA (1) CA2559629A1 (enExample)
IL (1) IL178011A0 (enExample)
MA (1) MA28531B1 (enExample)
NO (1) NO20064450L (enExample)
PE (1) PE20060078A1 (enExample)
RU (1) RU2378274C2 (enExample)
TW (1) TW200602051A (enExample)
WO (2) WO2005090352A1 (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
JP2007514704A (ja) * 2003-12-19 2007-06-07 グラクソ　グループ　リミテッド ピラゾロ［３，４−ｂ］ピリジン化合物およびホスホジエステラーゼ阻害剤としてのその使用
EP1735314A1 (en) * 2004-03-16 2006-12-27 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compound, and its use as a pde4 inhibitor
TW200811111A (en) 2006-04-20 2008-03-01 Glaxo Group Ltd Novel compounds
AR061571A1 (es) 2006-06-23 2008-09-03 Smithkline Beecham Corp Compuesto sal del acido toluenosulfonico de 4-{[6-cloro-3-({[(2- cloro-3-fluorofenil) amino]carbonil} amino)- 2- hidroxifenil]sulfonil] -1- piperazinacarbxilato de 1.1-dimetiletilo, composicion farmaceutica que lo comprende su uso para la fabricacion de un medicamento combinacion farmaceutica con un
WO2008015416A1 (en) 2006-08-01 2008-02-07 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
TW201000476A (en) 2008-02-06 2010-01-01 Glaxo Group Ltd Dual pharmacophores-PDE4-muscarinic antagonistics
TW200946526A (en) 2008-02-06 2009-11-16 Glaxo Group Ltd Dual pharmacophores-PDE4-muscarinic antagonistics
EP2249646A4 (en) * 2008-02-06 2013-09-25 Glaxo Group Ltd PDE4 muscarinic Antagonist-DOPPELPHARMACOPHOREN
AR070563A1 (es) 2008-02-06 2010-04-21 Glaxo Group Ltd Compuesto de un biciclo condensado pirazol-piridin-amina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento de enfermedades respiratorias.
GB0806900D0 (en) * 2008-04-16 2008-05-21 Dow Corning Fabric care emulsions
ES2566339T3 (es) 2008-06-05 2016-04-12 Glaxo Group Limited Derivados de 4-carboxamida indazol útiles como inhibidores de PI3-quinasas
CA2749403A1 (en) 2009-01-13 2010-09-02 Glaxo Group Limited Pyrimidinecarboxamide derivatives as inhibitors of syk kinase
US8524751B2 (en) 2009-03-09 2013-09-03 GlaxoSmithKline Intellecutual Property Development 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases
EP2406249A1 (en) 2009-03-10 2012-01-18 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
EP2408769A1 (en) 2009-03-17 2012-01-25 Glaxo Group Limited Pyrimidine derivatives used as itk inhibitors
MX2011010784A (es) * 2009-04-13 2012-01-12 Sulur Subramaniam Vanangamudi Una crema medicinal con acido fusidico hecha utilizando fusidato de sodio e incorporando un biopolimero y el proceso para hacerla.
ES2644724T3 (es) 2009-04-30 2017-11-30 Glaxo Group Limited Indazoles sustituidos con oxazol como inhibidores de PI3-cinasas
EP2507226A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Novel compounds
JP2013512879A (ja) 2009-12-03 2013-04-18 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤としてのベンズピラゾール誘導体
US20120238571A1 (en) 2009-12-03 2012-09-20 Glaxo Group Limited Indazole derivatives as pi 3-kinase
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
HUE026059T2 (en) 2010-09-08 2016-05-30 Glaxosmithkline Ip Dev Ltd N- [5- [4- (5 - {[(2R, 6S) -2,6-dimethyl-4-morpholinyl] methyl} -1,3-oxazol-2-yl) -1H-indazol-6-yl ] Polymorphs and salts of 2 - (methyloxy) -3-pyridinyl] methanesulfonamide
JP5876051B2 (ja) 2010-09-08 2016-03-02 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ インフルエンザウィルス感染の治療に使用するためのインダゾール誘導体
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
JP6202544B2 (ja) 2012-08-27 2017-09-27 アクティエボラゲット エレクトロラックス ロボット位置決めシステム
CN105101855A (zh) 2013-04-15 2015-11-25 伊莱克斯公司 具有伸出的侧刷的机器人真空吸尘器
JP6217952B2 (ja) 2013-04-15 2017-10-25 アクティエボラゲット エレクトロラックス ロボット真空掃除機
US9011934B2 (en) 2013-06-14 2015-04-21 SatisPharma, LLC Multi-purpose anti-itch treatment
AU2014336250A1 (en) 2013-10-17 2016-04-14 Glaxosmithkline Intellectual Property Development Limited PI3K inhibitor for treatment of respiratory disease
US20160263109A1 (en) 2013-10-17 2016-09-15 Glaxosmithkline Intellectual Property Development Limited P13k inhibitor for treatment of respiratory disease
EP3084539B1 (en) 2013-12-19 2019-02-20 Aktiebolaget Electrolux Prioritizing cleaning areas
JP6750921B2 (ja) 2013-12-19 2020-09-02 アクチエボラゲット エレクトロルックス ロボット掃除機
JP6687286B2 (ja) 2013-12-19 2020-04-22 アクチエボラゲット エレクトロルックス ロボット掃除機およびランドマーク認識方法
WO2015090402A1 (en) 2013-12-19 2015-06-25 Aktiebolaget Electrolux Robotic cleaning device with perimeter recording function
EP3082541B1 (en) 2013-12-19 2018-04-04 Aktiebolaget Electrolux Adaptive speed control of rotating side brush
JP6638988B2 (ja) 2013-12-19 2020-02-05 アクチエボラゲット エレクトロルックス サイドブラシを有し、渦巻きパターンで動くロボットバキュームクリーナ
CN105813528B (zh) 2013-12-19 2019-05-07 伊莱克斯公司 机器人清洁设备的障碍物感测爬行
KR102116595B1 (ko) 2013-12-20 2020-06-05 에이비 엘렉트로룩스 먼지통
JP2017515840A (ja) 2014-05-12 2017-06-15 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ 感染症を治療するためのダニリキシンを含む医薬組成物
EP3167341B1 (en) 2014-07-10 2018-05-09 Aktiebolaget Electrolux Method for detecting a measurement error in a robotic cleaning device
US10729297B2 (en) 2014-09-08 2020-08-04 Aktiebolaget Electrolux Robotic vacuum cleaner
KR102271785B1 (ko) 2014-09-08 2021-06-30 에이비 엘렉트로룩스 로봇 진공 청소기
US9452178B1 (en) 2014-10-22 2016-09-27 SatisPharma, LLC Acne formulations, treatments, and pressure sensitive patches for delivery of acne formulations
EP3230814B1 (en) 2014-12-10 2021-02-17 Aktiebolaget Electrolux Using laser sensor for floor type detection
US10874271B2 (en) 2014-12-12 2020-12-29 Aktiebolaget Electrolux Side brush and robotic cleaner
KR102326401B1 (ko) 2014-12-16 2021-11-16 에이비 엘렉트로룩스 로봇 청소 장치를 위한 청소 방법
KR102339531B1 (ko) 2014-12-16 2021-12-16 에이비 엘렉트로룩스 로봇 청소 장치를 위한 경험-기반의 로드맵
WO2016165772A1 (en) 2015-04-17 2016-10-20 Aktiebolaget Electrolux Robotic cleaning device and a method of controlling the robotic cleaning device
EP3344104B1 (en) 2015-09-03 2020-12-30 Aktiebolaget Electrolux System of robotic cleaning devices
WO2017060874A1 (en) * 2015-10-09 2017-04-13 Abbvie S.Á.R.L N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
CN108603935A (zh) 2016-03-15 2018-09-28 伊莱克斯公司 机器人清洁设备以及机器人清洁设备进行陡壁检测的方法
EP3454707B1 (en) 2016-05-11 2020-07-08 Aktiebolaget Electrolux Robotic cleaning device
EP3497100A1 (en) 2016-08-08 2019-06-19 GlaxoSmithKline Intellectual Property Development Limited Chemical compounds
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
US11474533B2 (en) 2017-06-02 2022-10-18 Aktiebolaget Electrolux Method of detecting a difference in level of a surface in front of a robotic cleaning device
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
JP6989210B2 (ja) 2017-09-26 2022-01-05 アクチエボラゲット エレクトロルックス ロボット清掃デバイスの移動の制御
KR102034538B1 (ko) * 2017-11-28 2019-10-21 주식회사한국파마 Jak 저해제 화합물, 및 이의 제조방법
CN111875594A (zh) * 2020-07-21 2020-11-03 中国药科大学 具有磷酸二酯酶4b抑制活性的吲唑杂环类化合物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3856799A (en) * 1971-08-05 1974-12-24 Squibb & Sons Inc Intermediates for production of amino derivatives of pyrazolopyridine carboxylic acids and esters
US3925388A (en) * 1971-08-05 1975-12-09 Squibb & Sons Inc 4-Piperazino-{8 3,4-b{9 pyridine-5-carboxylic acids and esters
BE787249A (fr) * 1971-08-05 1973-02-05 Squibb & Sons Inc Derives amino d'acides pyrazolopyridine carboxyliques, leurs esters et les sels de ces composes, ainsi que leurs procedes de preparation
US3833594A (en) 1971-08-05 1974-09-03 Squibb & Sons Inc Amino derivatives of pyrazolopyridine carboxylic acids and esters
CA1003419A (en) 1971-11-23 1977-01-11 Theodor Denzel Process for the production of pyrazolo (3,4-b) pyridines
US3840546A (en) 1972-11-15 1974-10-08 Squibb & Sons Inc Amino derivatives of pyrazolopyridine carboxamides
US3979399A (en) 1972-11-15 1976-09-07 E. R. Squibb & Sons, Inc. Amino derivatives of pyrazolopyridine carboxamides
US3833598A (en) 1972-12-29 1974-09-03 Squibb & Sons Inc Amino derivatives of pyrazolopyridine-6-carboxylic acids and esters
US4115394A (en) 1974-05-06 1978-09-19 E. R. Squibb & Sons, Inc. Amino derivatives of 6-phenylpyrazolo[3,4-b]pyridines
US4364948A (en) 1981-09-28 1982-12-21 Ici Americas Inc. Pyrazolo[3,4-b]pyridine compounds
GB8425104D0 (en) * 1984-10-04 1984-11-07 Ici America Inc Amide derivatives
US5547954A (en) * 1994-05-26 1996-08-20 Fmc Corporation 2,4-Diamino-5,6-disubstituted-and 5,6,7-trisubstituted-5-deazapteridines as insecticides
US5593997A (en) 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US6326379B1 (en) * 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
RU2134498C1 (ru) * 1998-12-08 1999-08-10 Таран Александр Иванович Контактный узел
OA12050A (en) 1999-09-30 2006-05-02 Neurogen Corp Certain alkylene diamine-substituted heterocycles.
GB9929685D0 (en) 1999-12-15 2000-02-09 Merck Sharp & Dohme Therapeutic agents
JP2002020386A (ja) * 2000-07-07 2002-01-23 Ono Pharmaceut Co Ltd ピラゾロピリジン誘導体
US6670364B2 (en) * 2001-01-31 2003-12-30 Telik, Inc. Antagonists of MCP-1 function and methods of use thereof
US7342021B2 (en) 2001-02-08 2008-03-11 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
TWI236474B (en) 2001-04-03 2005-07-21 Telik Inc Antagonists of MCP-1 function and methods of use thereof
US20050043319A1 (en) * 2001-08-14 2005-02-24 Exonhit Therapeutics Sa Molecular target of neurotoxicity
FR2828693B1 (fr) * 2001-08-14 2004-06-18 Exonhit Therapeutics Sa Nouvelle cible moleculaire de la neurotoxicite
DE60329193D1 (de) 2002-09-16 2009-10-22 Glaxo Group Ltd Pyrazolo(3,4-b)pyridinverbindungen und ihre verwendung als phosphodiesterasinhibitoren
GB0230045D0 (en) * 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
US7117650B2 (en) * 2002-12-09 2006-10-10 Forrest Dockery Hanger system
JP2007514704A (ja) * 2003-12-19 2007-06-07 グラクソ　グループ　リミテッド ピラゾロ［３，４−ｂ］ピリジン化合物およびホスホジエステラーゼ阻害剤としてのその使用
GB0405933D0 (en) 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds
GB0405937D0 (en) 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds
EP1735314A1 (en) 2004-03-16 2006-12-27 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compound, and its use as a pde4 inhibitor

Also Published As

Publication number Publication date
US7709497B2 (en) 2010-05-04
WO2005090352A1 (en) 2005-09-29
US20080275078A1 (en) 2008-11-06
EP1735314A1 (en) 2006-12-27
PE20060078A1 (es) 2006-03-10
RU2378274C2 (ru) 2010-01-10
JP2007529464A (ja) 2007-10-25
EP1740590A1 (en) 2007-01-10
RU2006132684A (ru) 2008-04-27
IL178011A0 (en) 2006-12-31
MA28531B1 (fr) 2007-04-03
AR048175A1 (es) 2006-04-05
WO2005090354A1 (en) 2005-09-29
BRPI0508843A (pt) 2007-08-28
CA2559629A1 (en) 2005-09-29
US20070280971A1 (en) 2007-12-06
KR20060130744A (ko) 2006-12-19
NO20064450L (no) 2006-11-14
JP2007529486A (ja) 2007-10-25
AU2005223351A1 (en) 2005-09-29

Similar Documents

Publication Publication Date Title
TW200602051A (en) Pyrazolo[3,4-b]pyridine compound, and its use as a PDE4 inhibitor
MY149046A (en) Benzenesulfonamide derivatives
NO20055421L (no) Kinolinderivater som fosfodiestrase-inhibitorer
WO2007044085A3 (en) Heteroaryl compounds and their uses as therapeutic agents
NO20054208L (no) Nitrogen-substituerte heksahydropyrazino[1,2-a]pyrimidin-4,7-dionderivater, fremgangsmater for fremstilling og anvendelse derav som medikamenter
MX2009002171A (es) Derivados de triazol como inhibidores de cinasas.
TW200612951A (en) New pyridazin-3(2h)-one derivatives
WO2007040438A3 (en) Novel imidazo [4,5 -b] pyridine derivatives as inhibitors of glycogen synthase kinase 3 for use in the treatment of dementia and neurodegenerative disorders
MX2020014163A (es) Formas solidas y formulaciones de (s)-4-(8-amino-3-(1-(but-2-inoil )pirrolidin-2-il)imidazo [1,5-a]pirazin-1-il)-n-(piridin-2-il)benz amida.
MY140748A (en) Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
NO20054085L (no) Substituerte heksahydropyrazino [1,2-a]pyrimidin-4,7-dionderivater, fremgangsmater for fremstilling og anvendelse derav som medikamenter
WO2002083667A3 (en) Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
AP2004003100A0 (en) Nicotinamide derivatives useful as PDE4 inhibitors
WO2009049180A3 (en) Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
WO2008045664A3 (en) Heterocyclic pde4 inhibitors as antiinflammatory agents
NO20044599L (no) 3-amino-tieno[2,3-b]pyridin-2-karboksysyreamid-forbindelser og fremgangsmater for fremstilling og anvendelser av dem
ATE365742T1 (de) 4-aminothieno(2,3-d) pyrimidin -6-carbonitril- derivative zur verwendung als pde7 inhibitoren
BRPI0714320A2 (pt) Derivado de imidazo[1,2-a] piridina-2-carboxamidas, sua preparação e sua aplicação em terapêutica
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
MY133303A (en) Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
NO20082159L (no) Triazolopyridinderivater som inhibitorer av lipaser og fosfolipaser
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
WO2006126082A3 (en) Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
ATE520668T1 (de) Sigmarezeptor-inhibitoren